Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + dacarbazine + doxorubicin + vinblastine
- Development stage
- Phase 3
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
ABVD is a chemotherapy combination regimen consisting of four drugs: doxorubicin (also known as Adriamycin), bleomycin, vinblastine, and dacarbazine. It is primarily used as first-line treatment for classic Hodgkin lymphoma. Each drug in the combination has a distinct mechanism of action targeting rapidly dividing cancer cells through different pathways: - Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Bleomycin induces DNA strand breaks via free radical formation. - Vinblastine disrupts microtubule assembly by binding tubulin. - Dacarbazine acts as an alkylating agent causing DNA methylation and cross-linking. The regimen is administered intravenously in cycles (typically every 28 days) with two treatments per cycle. ABVD has demonstrated high efficacy in inducing remission in Hodgkin lymphoma patients and remains a standard of care due to its balance of effectiveness and manageable toxicity profile[2][3][4][5].
- Brand names
- ABVD
- Other names
- doxorubicin, bleomycin, vinblastine, and dacarbazineAdriamycin-Bleomycin-Vinblastine-Dacarbazine
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on bleomycin + dacarbazine + doxorubicin + vinblastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + dacarbazine + doxorubicin + vinblastine.